ArticleTobacco control2025
Regional variations and market share of FDA-authorised products for top-selling electronic cigarette brands in the USA: 2022-2024.
Article in Tobacco control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Toxicant Exposures After Switching From Cigarettes to a Pod-Based Electronic Cigarette: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Switching from Cigarettes to E-Cigarettes and Oral Nicotine Pouches in Adults with Low-Income Who Smoke: Qualitative Findings from a Pilot Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Trial
- Standardized research electronic cigarette acceptability among adult men and women who smoke combustible cigarettes.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025Trial
- Illegal markets for cigarettes and e-cigarettes.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Rapid tobacco use surveillance: Confiscated tobacco products from United States Schools, 2021-2025.Preventive medicine reports · 2026Article
- Monitoring of tobacco product marketing for rapid public health surveillance in the United States.Preventive medicine reports · 2026Article
- Rapid tobacco surveillance among young people in six states: Methods and findings from the Center for Rapid Surveillance of Tobacco Youth and Young Adult Cohort.Preventive medicine reports · 2026Article
- Accelerating tobacco regulatory science in the United States: The center for rapid surveillance of tobacco.Preventive medicine reports · 2026Article
- Marketing expenditures and industry transformation: are cigarette companies really shifting away from cigarettes?Tobacco control · 2026Article
- Public health impact of disposable electronic cigarettes since 2021: a scoping review.Frontiers in public health · 2026Article
- Beliefs About e-Cigarette Regulation Among a Cohort of Long-Term Adult Users: A Thematic Analysis.Tobacco use insights · 2026Article
- Online e-Cigarette Retailers' Use of Price Incentives and Product Features to Attract Adolescent and Young Adult Purchases: Cross-Sectional Choice-Based Study.Journal of medical Internet research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis paper examines top-selling electronic cigarette (e-cigarette) brands and differences in top-selling brands by region in the USA from 2022 to 2024, and the market share of Food and Drug Administration (FDA)-authorised products in 2023 and 2024 using e-cigarette sales data from Nielsen's Convenience Track system.
methodsRegional analyses included sales data from eight US census divisions. We reported total unit sales and market share by brand, nationally and by region. Data on whether products had FDA marketing authorisation were obtained from FDA's Searchable Tobacco Product Database.
resultsNationally, Vuse, JUUL and NJOY comprised the majority of e-cigarette market share in 2022 (68.3%), 2023 (65.4%) and 2024 (57.5%), and Geek Bar emerged as the third top selling brand in 2024 (11.8%). Aside from these brands, there was a large variation in the top five brands by region across years. Approximately 13.8% of e-cigarette product sales in 2024 were authorised for sale by the FDA, as compared with 3.3% in 2023.
conclusionsThe differences in top brands by region reflect challenges in the surveillance of e-cigarette sales, marketing and use and reflect the rapidly changing disposable e-cigarette marketplace, in which new brands are introduced and popularised at high frequency, as manufacturers of disposable e-cigarettes adapt to exploit regulatory loopholes. In the context of other emerging markets, like nicotine pouches, we urge regulators to act quickly to regulate the market for these products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.